Published in AIDS on September 10, 2011
Impact of HLA-driven HIV adaptation on virulence in populations of high HIV seroprevalence. Proc Natl Acad Sci U S A (2014) 1.40
Frequent and variable cytotoxic-T-lymphocyte escape-associated fitness costs in the human immunodeficiency virus type 1 subtype B Gag proteins. J Virol (2013) 1.14
Distinct evolutionary pressures underlie diversity in simian immunodeficiency virus and human immunodeficiency virus lineages. J Virol (2012) 1.00
Has the rate of CD4 cell count decline before initiation of antiretroviral therapy changed over the course of the Dutch HIV epidemic among MSM? PLoS One (2013) 0.95
Immuno-epidemiological modeling of HIV-1 predicts high heritability of the set-point virus load, while selection for CTL escape dominates virulence evolution. PLoS Comput Biol (2014) 0.91
Genotypic and functional impact of HIV-1 adaptation to its host population during the North American epidemic. PLoS Genet (2014) 0.91
Broad and persistent Gag-specific CD8+ T-cell responses are associated with viral control but rarely drive viral escape during primary HIV-1 infection. AIDS (2015) 0.86
Estimating the fitness cost of escape from HLA presentation in HIV-1 protease and reverse transcriptase. PLoS Comput Biol (2012) 0.81
Impact of HLA selection pressure on HIV fitness at a population level in Mexico and Barbados. J Virol (2014) 0.78
High frequency of transmitted HIV-1 Gag HLA class I-driven immune escape variants but minimal immune selection over the first year of clade C infection. PLoS One (2015) 0.77
Population-Level Immune-Mediated Adaptation in HIV-1 Polymerase during the North American Epidemic. J Virol (2015) 0.75
Identification of a new human coronavirus. Nat Med (2004) 11.24
HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol (2002) 10.37
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS (2003) 5.85
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature (2012) 5.49
In vivo labeling with 2H2O reveals a human neutrophil lifespan of 5.4 days. Blood (2010) 4.84
Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol (2002) 3.59
Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci U S A (2012) 3.33
Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol (2004) 3.23
CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr (2007) 3.18
HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res (2005) 2.93
Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell (2013) 2.88
Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS (2004) 2.51
Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol Ther (2006) 2.48
The Ebola virus VP35 protein is a suppressor of RNA silencing. PLoS Pathog (2007) 2.48
Maintenance of peripheral naive T cells is sustained by thymus output in mice but not humans. Immunity (2012) 2.41
The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage. Immunogenetics (2005) 2.40
GB virus C coinfection and HIV-1 disease progression: The Amsterdam Cohort Study. J Infect Dis (2005) 2.33
Suppression of RNA interference by adenovirus virus-associated RNA. J Virol (2005) 2.29
A novel pancoronavirus RT-PCR assay: frequent detection of human coronavirus NL63 in children hospitalized with respiratory tract infections in Belgium. BMC Infect Dis (2005) 2.28
Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc Natl Acad Sci U S A (2005) 2.21
Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J Virol (2008) 2.16
Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition. Mol Ther (2008) 2.14
RNA interference against viruses: strike and counterstrike. Nat Biotechnol (2007) 2.14
Viral evolution as a tool to improve the tetracycline-regulated gene expression system. J Biol Chem (2004) 2.06
In HIV-1 pathogenesis the die is cast during primary infection. AIDS (2007) 2.04
Croup is associated with the novel coronavirus NL63. PLoS Med (2005) 2.03
International network for comparison of HIV neutralization assays: the NeutNet report. PLoS One (2009) 2.03
Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J Infect Dis (2010) 1.95
Detection of new viruses by VIDISCA. Virus discovery based on cDNA-amplified fragment length polymorphism. Methods Mol Biol (2008) 1.95
Viral replication capacity as a correlate of HLA B57/B5801-associated nonprogressive HIV-1 infection. J Immunol (2007) 1.89
Recognition of homo- and heterosubtypic variants of influenza A viruses by human CD8+ T lymphocytes. J Immunol (2004) 1.87
Retroviral superinfection resistance. Retrovirology (2005) 1.82
Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection. AIDS (2003) 1.81
A novel long distance base-pairing interaction in human immunodeficiency virus type 1 RNA occludes the Gag start codon. J Biol Chem (2002) 1.81
Differential transmission of human immunodeficiency virus type 1 by distinct subsets of effector dendritic cells. J Virol (2002) 1.78
HLA alleles associated with slow progression to AIDS truly prefer to present HIV-1 p24. PLoS One (2007) 1.77
Persistent numbers of tetramer+ CD8(+) T cells, but loss of interferon-gamma+ HIV-specific T cells during progression to AIDS. Blood (2002) 1.73
The leader of human immunodeficiency virus type 1 genomic RNA harbors an internal ribosome entry segment that is active during the G2/M phase of the cell cycle. J Virol (2003) 1.71
Inhibition of virus replication by RNA interference. J Biomed Sci (2003) 1.70
Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron. Nucleic Acids Res (2008) 1.65
Factor correction as a tool to eliminate between-session variation in replicate experiments: application to molecular biology and retrovirology. Retrovirology (2006) 1.64
Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. J Virol (2004) 1.64
Sparse production but preferential incorporation of recently produced naive T cells in the human peripheral pool. Proc Natl Acad Sci U S A (2008) 1.62
Highly sensitive methods based on seminested real-time reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 unspliced and multiply spliced RNA and proviral DNA. J Clin Microbiol (2008) 1.61
Management of Epstein-Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconstitution. Clin Infect Dis (2006) 1.59
The novel human coronaviruses NL63 and HKU1. J Virol (2006) 1.59
Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure. Proc Natl Acad Sci U S A (2011) 1.58
Identification of sequential viral escape mutants associated with altered T-cell responses in a human immunodeficiency virus type 1-infected individual. J Virol (2003) 1.57
HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. AIDS (2008) 1.56
Low-level CD4+ T cell activation is associated with low susceptibility to HIV-1 infection. J Immunol (2005) 1.56
Differential usage of cellular niches by cytomegalovirus versus EBV- and influenza virus-specific CD8+ T cells. J Immunol (2006) 1.55
Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5. J Virol (2004) 1.53
The development of CD4 binding site antibodies during HIV-1 infection. J Virol (2012) 1.53
No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial. PLoS Med (2012) 1.52
Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur J Epidemiol (2007) 1.52
Selective decrease in circulating V alpha 24+V beta 11+ NKT cells during HIV type 1 infection. J Immunol (2002) 1.52
Multiple secondary structure rearrangements during HIV-1 RNA dimerization. Biochemistry (2002) 1.50
Thymic output: a bad TREC record. Nat Immunol (2003) 1.50
Human immunodeficiency virus type 1 escape is restricted when conserved genome sequences are targeted by RNA interference. J Virol (2007) 1.50
Microprocessor, Setx, Xrn2, and Rrp6 co-operate to induce premature termination of transcription by RNAPII. Cell (2012) 1.49
MHC class I molecules exploit the low G+C content of pathogen genomes for enhanced presentation. Eur J Immunol (2010) 1.49
Association of HLA-C and HCP5 gene regions with the clinical course of HIV-1 infection. AIDS (2009) 1.48
The effect of Trim5 polymorphisms on the clinical course of HIV-1 infection. PLoS Pathog (2008) 1.41
The tRNA primer activation signal in the human immunodeficiency virus type 1 genome is important for initiation and processive elongation of reverse transcription. J Virol (2002) 1.40
Mosaic structure of human coronavirus NL63, one thousand years of evolution. J Mol Biol (2006) 1.40
Proteomic studies reveal coordinated changes in T-cell expression patterns upon infection with human immunodeficiency virus type 1. J Virol (2008) 1.40
Influence of donor cytomegalovirus (CMV) status on severity of viral reactivation after allogeneic stem cell transplantation in CMV-seropositive recipients. Clin Infect Dis (2011) 1.40
Genome structure and transcriptional regulation of human coronavirus NL63. Virol J (2004) 1.39
Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort. PLoS One (2011) 1.38
Cell-associated HIV RNA: a dynamic biomarker of viral persistence. Retrovirology (2013) 1.37
Human coronavirus NL63, a new respiratory virus. FEMS Microbiol Rev (2006) 1.37
Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function. Virology (2010) 1.36
The HIV-1 leader RNA conformational switch regulates RNA dimerization but does not regulate mRNA translation. Biochemistry (2005) 1.36
Failing immune control as a result of impaired CD8+ T-cell maturation: CD27 might provide a clue. Trends Immunol (2002) 1.36
Low immune activation despite high levels of pathogenic human immunodeficiency virus type 1 results in long-term asymptomatic disease. J Virol (2007) 1.35
Human immunodeficiency virus type 1 subtypes have a distinct long terminal repeat that determines the replication rate in a host-cell-specific manner. J Virol (2004) 1.34
Lewis X component in human milk binds DC-SIGN and inhibits HIV-1 transfer to CD4+ T lymphocytes. J Clin Invest (2005) 1.34
Lack of detection of XMRV in seminal plasma from HIV-1 infected men in The Netherlands. PLoS One (2010) 1.34
Association study of common genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200 controls. PLoS Pathog (2013) 1.33
Deep sequencing of virus-infected cells reveals HIV-encoded small RNAs. Nucleic Acids Res (2011) 1.32
T-cell receptor excision circle and T-cell dynamics after allogeneic stem cell transplantation are related to clinical events. Blood (2002) 1.31
Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression. AIDS (2009) 1.31
A comparative study of HLA binding affinity and ligand diversity: implications for generating immunodominant CD8+ T cell responses. J Immunol (2009) 1.30
A miRNA-tRNA mix-up: tRNA origin of proposed miRNA. RNA Biol (2010) 1.30
A riboswitch regulates RNA dimerization and packaging in human immunodeficiency virus type 1 virions. J Virol (2004) 1.30